Western blotting and immunoprecipitation assays on NSCLC harboring EML4-ALK fusion transcript. A: Testing of anti-ALK mAb (ALKc) in Western blot and immunoprecipitation. Left: Western blot analysis on cell lysates of Rh30, Karpas 299 and H2228 cell lines, expressing full-length ALK (about 200 kDa), NPM-ALK (80 kDa), and the short form of EML4-ALK (about 90 kDa), respectively. Right: ALKc is able to recognize and immunoprecipitate the EML4-ALK fusion protein variant 1 (about 120 kDa) from the Phoenix cells transfected with EML4-ALK fusion gene construct, variant 1 (Px_EML4-ALK). The lower molecular weight bands appearing in the membrane likely represent degradation products of the over-expressed protein. B: Western blot analysis on EML4-ALK-positive samples: a band corresponding to EML4-ALK fusion protein (variant 1, about 120 kDa, left; variant 3, about 90 kDa, right) is not detectable in either NSCLC (cases B/252T, B/5796T, B/8237T, B/9020T, 424T, 447T for variant 1; 470T for variant 3) or non-neoplastic patient samples (cases 446N and 442N for variant 3). RIPA extracts or whole cell lysates, WCL. The membrane was stripped and reblotted with anti-Hsp90 rabbit polyclonal antibody (lower panels). C: Absence of detectable EML4-ALK fusion protein in the ALK-immunoprecipitates from EML4-ALK-positive NSCLC patient samples. As positive controls for ALK-immunoprecipitation, the H2228 and the Phoenix cell line transfected with EML4-ALK fusion gene construct, variant 1 (Px_EML4-ALK) were used. As positive control, immunoprecipitation of Hsp90 from one out of six NSCLC samples was performed. The same membrane was blotted with ALKc mAb (upper) and then stripped and reblotted with anti-Hsp90 rabbit polyclonal antibody (lower). D: Same experiment as in (C) was conducted on one EML4-ALK-positive non-tumor lung tissue sample (397N).